Drug Profile


Alternative Names: BHV-4157; FC 4157

Latest Information Update: 05 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinocerebellar degeneration

Most Recent Events

  • 27 Jul 2017 The State University of New Jersey and National Cancer Institute plan a phase I trial for Solid tumours and Lymphoma (Combination therapy, Metastatic disease, Inoperable/unresectable, Late-stage disease) in USA (NCT03229278)
  • 30 May 2017 Biohaven Pharmaceutical completes enrolment in its phase II/III trial for Spinocerebellar ataxia in USA
  • 15 May 2017 Trigriluzole receives Fast Track designation for Spinocerebellar degeneration [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top